EP0666761A1 - Stimulation d'une reponse antitumorale des lymphocytes t a l'aide d'anticorps anti-idiotypiques - Google Patents

Stimulation d'une reponse antitumorale des lymphocytes t a l'aide d'anticorps anti-idiotypiques

Info

Publication number
EP0666761A1
EP0666761A1 EP93920425A EP93920425A EP0666761A1 EP 0666761 A1 EP0666761 A1 EP 0666761A1 EP 93920425 A EP93920425 A EP 93920425A EP 93920425 A EP93920425 A EP 93920425A EP 0666761 A1 EP0666761 A1 EP 0666761A1
Authority
EP
European Patent Office
Prior art keywords
tumor
antibody
response
antitumor
cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93920425A
Other languages
German (de)
English (en)
Other versions
EP0666761A4 (fr
Inventor
Lynn E. Spitler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jenner Technologies
Original Assignee
Jenner Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenner Technologies filed Critical Jenner Technologies
Publication of EP0666761A1 publication Critical patent/EP0666761A1/fr
Publication of EP0666761A4 publication Critical patent/EP0666761A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the invention is related to the field of interfering with the progression of malignancies or other tumors. More specifically, the invention concerns use of anti- idiotypic antibodies to produce an antitumor cytotoxic and/or helper T-cell response.
  • mice with an anti-id preparation that appears to mimic the tumor antigen structure is said to induce anti-tumor immunity in tumor-bearing animals or humans
  • Nepom, G.T. et al . Proc Natl Acad Sci USA (1984) 8JL :2864-2867; Gorczynski, R.M. et al . , Cancer Res (1984) 4_4:3291-3298; Dunn, P.L. et al . , Immunol (1987) 60:181- 186) .
  • the paper also cites an additional report by Herlyn, D.A. et al.
  • the present invention concerns the use of anti- idiotypic antibodies to induce an antitumor T-cell response in tumor-bearing subjects.
  • the invention results from the recognition that the essential elements of the ability of anti-idiotypic antibodies to mediate antitumor activity in a subject resides in their ability to cause the subject to mount a T-cell response to a tumor associated antigen (TAA) .
  • TAA tumor associated antigen
  • the invention involves monitoring the T-cell response of the subject and in aiding the subject in mounting such a response by supplying the anti-id in conjunction with at least one adjuvant which stimulates T-cell response.
  • the invention is directed to a method to induce and monitor an antitumor T-cell mediated response in a tumor-bearing subject which method comprises administering an anti-idiotypic antibody to the subject.
  • the anti-idiotypic antibody has an internal image that mimics a tumor associated antigen characteristic of the tumor that afflicts the subject. The subject is monitored to ensure that a T-cell response is obtained and the protocol can then be adjusted accordingly.
  • the invention is directed to a composition which is useful to elicit an antitumor T-cell-mediated response.
  • the composition contains, in addition to at least one anti-idiotypic antibody with an internal image that mimics the relevant tumor associated antigen, an adjuvant which encourages a T-cell response in the subject.
  • the invention is directed to a method of treatment using these compositions.
  • anti-idiotypic antibody is used in its art-recognized sense.
  • antibodies capable of binding that antigen specifically do so because of a region of the antibody which is an "idiotype” unique to antibodies raised with regard to the stimulating antigen.
  • the conventional antibody-antigen specific immunoreactivity which is used to advantage, for example, in the conduct of immunoassays, relies on the ability of "idiotypic” antibodies to bind antigen.
  • the idiotypic region of the antibody is not perfectly coextensive with the "paratope", i.e., that region which is most complementary to the epitope residing on the antigen. However, the same general regions of the antibody are involved.
  • anti-idiotypic antibodies raised in response to the antigen immunization are themselves treated as antigens, either because they are deliberately administered, or by virtue of their generation in si tu in the first immunization, a secondary population of antibodies called "anti-idiotypic" antibodies is raised. These are antibodies which have unique regions by virtue of their ability to bind the idiotypic antibodies. A certain portion of these anti-idiotypic antibodies will mimic the structure of the epitope presented by the original antigen and to which the anti-ids bind. This subset of the anti-idiotypic population thus in effect behaves in a manner similar to the original antigen.
  • the anti-idiotypic antibodies of the invention are those which bear such an internal image--i.e., they mimic a tumor associated antigen which characterizes the tumor against which a T-cell response is to be mounted.
  • the idiotypic or anti-idiotypic regions of antibodies are located in the immunoreactive portions of the antibody molecule.
  • antibodies unless otherwise specified or evident from the context, are intended to include such immunologically reactive fragments, such as, most commonly, Fab, Fab' , and F(ab') 2 fragments. Ways to prepare both monoclonal and polyclonal anti- idiotypic antibodies which mimic tumor associated antigens is described in detail in U.S. Patent 5,053,224, the disclosure of which is incorporated herein by reference. Briefly, polyclonal anti-idiotypic antibodies may be produced by immunizing animals with monoclonal idiotypic antibodies and screening for antisera which react with idiotypic antibodies to tumor associated antigens. Preferably, a competition assay between the TAA and the antisera is employed; the anti-ids which mimic the antigen are successful competitors.
  • the antisera can be purified by sequential adsorption with immobilized antibody of the same isotype as the monoclonal idiotypic antibody but a different idiotype in order to remove antiisotypic antibodies from the antisera and then with the immobilized monoclonal idiotypic antibody to remove the remaining anti-ids.
  • the purified sera can then be again tested for their ability to bind idiotypic antibodies in competition with TAA.
  • Monoclonal antibody preparations from such animals may also be prepared using standard techniques of immortalizing the antibody secreting cells of the animal and screening the cultures with idiotypic antibodies in competition with TAA. Human or murine monoclonals are preferred; polyclonal preparations in a variety of mammalian systems may also be used.
  • anti-idiotypic antibodies of the invention and the immunologically reactive fragments thereof may also be produced using recombinant techniques provided the relevant portions are sequenced so as to permit the construction of suitable variable regions. Recombinant production of such antibodies or fragments permits the use of chimeric antibodies as well as those natively produced.
  • the anti-idiotypic antibodies are administered for both prevention and treatment of malignancy including solid tumors, for example, tumors located in the lung, colon, rectum, stomach, breast, prostate, pancreas, uterus, ovary, urinary tract, skin, oral cavity, liver, bone, brain, endocrine glands, connective tissue, esophagus, eye and melanoma as well as malignancies of the blood and lymph nodes such as leukemia, lymphoma, and multiple myeloma.
  • malignancy including solid tumors, for example, tumors located in the lung, colon, rectum, stomach, breast, prostate, pancreas, uterus, ovary, urinary tract, skin, oral cavity, liver, bone, brain, endocrine glands, connective tissue, esophagus, eye and melanoma as well as malignancies of the blood and lymph nodes such as leukemia, lymphoma, and multiple myeloma.
  • the anti-idiotypic antibodies of the invention are administered as antitumor vaccines to subjects at risk for the development of malignancy or showing a diagnosis thereof.
  • the compositions are formulated for parenteral administration or for aerosol administration using formulations appropriate to the administration route, such as those described in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Company, Easton, PA.
  • Suitable routes for parenteral administration include injection, including intraperitoneal, intramuscular, intravenous, and subcutaneous injection.
  • the antibodies are generally formulated in a suitable liquid such as Hank's solution or Ringer's solution, along with suitable excipients providing buffering, stabilizing, and other desirable characteristics, as well as additional components if desired as further described below.
  • Alternative routes for parenteral administration include transmucosal and transdermal administration, generally involving excipients which enhance permeation such as bile salts, fusidic acids, detergents, and the like.
  • additional components for stabilizing the aerosol may also be included.
  • liposomes are desirably used as a carrier to direct the product to the immune system as disclosed in copending application 07/800,474, the disclosure of which is incorporated herein by reference.
  • the dosage range for the antibodies of the invention is of the order of 0.01 ⁇ g-100 mg per dose, preferably 0.1 ⁇ g-10 mg per dose, and more preferably 1 mg-5 mg per dose.
  • Suitable volumes for parenteral administration are about 0.1-5 ml.
  • the antibodies of the invention are administered, generally, in multiple doses typically once per week for one or two months and with decreasing frequency thereafter for a period extending about one year.
  • booster inoculations may be given every two months to five years. Alternate protocols may be appropriate in individual instances.
  • viral vectors are described, for example, by Hruby, D.E., Vet Parasitol (1988) 21:281-282, and by Iiu, S.-I., in "AIDS Research Reviews,” Dekker, Inc., (1991) . 1:403- 416.
  • the viral vectors may be administered in the traditional manner via a skin scratch, or may be included in a liposome injectable as described above.
  • antibodies of the invention may be administered alone, it is a further feature of the invention that these antibodies are administered along with adjuvants which enhance the cellular immune response to the anti-idiotypic antibody.
  • adjuvants include, but are not limited to, Freund' s Complete Adjuvant, Bacillus Calmette-Guerin (BCG) and other bacteria, adjuvant polysaccharides such as glucan, acemannan, lentinan; saponins, detoxified endotoxin (DETOX) , muramyl tripeptide, muramyl dipeptide and their derivatives, SAF1, lymphokines and cytokines such as IL-2 and interferon as well as colony stimulating factors such as GM-CSF, lipid A, monophosphoryl lipid A, alum or immune stimulating complexes in general (ISCOMS) .
  • the efficacy of the treatment is monitored using measurements of the cellular immune response.
  • Such monitoring permits adjustment of the protocol to enhance the effectiveness of the drugs .
  • the assessment of T-cell response is conducted, first, immediately before the start of the protocol in order to establish a baseline; and then determinations are made weekly, biweekly or monthly after the start of the protocol for about 6 months and at decreased frequency thereafter.
  • any convenient timing strategy appropriate to the individual case may be used.
  • a number of methods for monitoring cellular immune response are available.
  • test reaction which is a classic measure of cellular activity which is described in detail as applied to patient testing by Spitler, L.E., in "Manual of Clinical Immunology", Rose, N.R. et al . , eds. , Am Soc Microbiol, Washington, D.C. (1976) pgs. 53-63.
  • a test antigen is injected intradermally in about 0.1 ml saline or other isotonic solvent and the reaction is read 24-48 hours after injection.
  • the reaction consists of the development of erythema and induration at the test site with associated characteristic histopathological changes. These changes may be demonstrated by biopsy.
  • the immunizing antibody cannot be used as the test antigen since positive response would simply reflect reactivity to the murine component of the immunogen.
  • Tumor cells or their extracts or pure tumor antigens should be used as the test antigen.
  • Controls include injection of the solvent alone to rule out nonspecific dermal reactivity or injection of unrelated tumor cells or antigen to demonstrate specificity.
  • Another test for cellular response comprises lymphocyte stimulation. In this approach, the response of the patient's lymphocytes to the test antigens and suitable controls is measured in vitro.
  • the toxicity of the subject's peripheral blood or lymph node lymphocytes to tumor cells can be measured ex vivo in a standard radioactive chromium release assay as described by Yanelli, J.R. et al. , J Immunol (1985) 135:900-905.
  • Purified lymphocytes from the test subject are cultured with 51 Cr tagged tumor cells; varying numbers of effector cells are added to the tumor cells in microtiter plates and the plates are incubated for sufficient time to release label into the supernatant. The supernatants are then removed and counted.
  • cytolytic lymphocyte precursors can be conducted.
  • This method which is more sensitive than the lymphocyte toxicity method of the previous paragraph involves restimulation of lymphocytes in the peripheral blood by tumor cells or antigen in vi tro. This causes proliferation of the target cell as described by Vose, B.M. et al . , Int J Cancer (1982) 3_0:135-142 and by Mitchell, M.S. et al. , Cancer Res (1988) 48 . :5883-5893.
  • the method measures both precursors of cytolytic lymphocytes and mature effector cells .
  • Purified peripheral blood lymphocytes from the test subject are cultured with irradiated tumor cells, using appropriate controls.
  • the tumor cells are labeled with radioactive chromium and added to the cultured lymphocyte/tumor cell mixture. Results are assessed by determining the radioactive chromium release after an additional period of culture.
  • the specificity of the cytolytic reaction can be determined by using different target cell lines such as irrelevant tumors of the same and different histological types as that represented by the immunizing antibody.
  • interleukin-2 in plasma can be used as an index in vivo of T-cell activation. Plasma levels of IL- 2 can be measured conveniently using standard ELISA assays, for example. One such assay is described by Robins, R.A. et al. , Cancer Res (1991) 51:5425-5429.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Des anticorps anti-idiotypiques contenant des images internes qui simulent des antigènes associés à une tumeur sont utilisés comme vaccins pour stimuler une réponse immune des lymphocytes T chez un sujet porteur de tumeur ou chez un sujet exposé à des tumeurs malignes. On administre les anticorps et on contrôle la réponse des lymphocytes T du sujet afin d'évaluer l'efficacité des protocoles et/ou on administre les anticorps en combinaison avec un adjuvant connu pour activer les réponses des lymphocytes T.
EP93920425A 1992-08-31 1993-08-31 Stimulation d'une reponse antitumorale des lymphocytes t a l'aide d'anticorps anti-idiotypiques. Withdrawn EP0666761A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US938079 1978-08-30
US93807992A 1992-08-31 1992-08-31
PCT/US1993/008163 WO1994005329A1 (fr) 1992-08-31 1993-08-31 Stimulation d'une reponse antitumorale des lymphocytes t a l'aide d'anticorps anti-idiotypiques

Publications (2)

Publication Number Publication Date
EP0666761A1 true EP0666761A1 (fr) 1995-08-16
EP0666761A4 EP0666761A4 (fr) 1996-07-17

Family

ID=25470841

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93920425A Withdrawn EP0666761A4 (fr) 1992-08-31 1993-08-31 Stimulation d'une reponse antitumorale des lymphocytes t a l'aide d'anticorps anti-idiotypiques.

Country Status (5)

Country Link
EP (1) EP0666761A4 (fr)
JP (1) JPH08502954A (fr)
AU (1) AU5097393A (fr)
CA (1) CA2139743A1 (fr)
WO (1) WO1994005329A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798100A (en) * 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US7354587B1 (en) 1994-07-06 2008-04-08 Immunomedics, Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
EP1298144A3 (fr) 1994-12-28 2006-05-31 University of Kentucky Research Foundation Anticorps monoclonal anti-idiotype murin 3H1
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
WO1999045018A1 (fr) * 1998-03-06 1999-09-10 Imclone Systems Incorporated Immunisation active contre les antigenes associes a l'angiogenese
US6376654B1 (en) 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
US7226750B1 (en) 2000-08-08 2007-06-05 Molecular Discoveries, Inc. Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
US8551480B2 (en) 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8562988B2 (en) 2005-10-19 2013-10-22 Ibc Pharmaceuticals, Inc. Strategies for improved cancer vaccines
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8652484B2 (en) 2004-02-13 2014-02-18 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435539B2 (en) 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
CN102186499B (zh) 2008-08-20 2015-05-20 Ibc医药公司 用于癌症治疗的对接和锁定(dnl)疫苗

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 9, no. 2, 1989, pages 109-124, XP000569759 RAYCHAUDHURI S. ET AL.: *
INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 7, no. 4, 1991, pages 245-257, XP000569562 HERLYN D.ET AL.: *
INTERNATIONAL REVIEWS OF IMMUNOLOGY, vol. 7, no. 4, 1991, pages 289-302, XP000570399 BHATTACHARYA-CHATTERJEE M. ET AL.: *
JOURNAL OF IMMUNOLOGY, vol. 139, no. 6, 15 September 1987, BALTIMORE US, pages 2096-2102, XP002003096 RAYCHAUDHURI S. ET AL.: *
See also references of WO9405329A1 *

Also Published As

Publication number Publication date
AU5097393A (en) 1994-03-29
EP0666761A4 (fr) 1996-07-17
CA2139743A1 (fr) 1994-03-17
WO1994005329A1 (fr) 1994-03-17
JPH08502954A (ja) 1996-04-02

Similar Documents

Publication Publication Date Title
Mittelman et al. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23
O'Boyle et al. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn
Bhattacharya-Chatterjee et al. Anti-idiotype vaccine against cancer
Raychaudhuri et al. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta).
US20070036798A1 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
AU596070B2 (en) Anti-idiotype antibodies & their use in inducing immulogical response to viruses & tumours
WO1994005329A1 (fr) Stimulation d'une reponse antitumorale des lymphocytes t a l'aide d'anticorps anti-idiotypiques
Rodolfo et al. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases
AU633492B2 (en) Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen
Quan Jr et al. Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: a phase I/II trial of I-Mel-2 plus SAF-m.
WO1989005309A1 (fr) Procede et moyen de selection d'anticorps anti-idiotype et leur utilisation pour le diagnostic, le controle, le traitement et/ou la prevention de maladies cancereuses, auto-immunes ou infectieuses
US5882654A (en) Polyvalent melanoma vaccine
Samonigg et al. Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody
Chatterjee et al. Anti-idiotype monoclonal antibodies as vaccines for human cancer
Chakraborty et al. Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody
Wikstrand et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system
DeFreitas et al. Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen
Birebent et al. Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17-1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients
US5840317A (en) Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen
Buckley et al. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses
US20090202560A1 (en) Method for diagnosing efficacy of xenotypic antibody therapy
Kageshita et al. Murjne Anti‐Idiotypic Monoclonal Antibodies to Syngeneic Antihuman High Molecular Weight‐Melanoma Associated Antigen Monoclonal Antibodies: Development, Characterization, and Clinical Applications
Bhattacharya-Chatterjee et al. Anti-idiotype antibody vaccine therapies of cancer
US5854069A (en) GD2 anti-idiotypic antibodies and uses thereof
Arlen et al. Monoclonal antibodies and their role in modulation of the immune response

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19960531

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19980303